Shooting for a new standard on osteoarthritis, Merck KGaA outlines promising data for a potential game-changer

Merck KGaA’s pharma group is taking one more step in a long journey toward rehabbing its rep in the R&D field this weekend. Company execs turned up at the ACR scientific conference in San Diego to roll out a promising look at some key Phase II osteoarthritis data — which comes with a critical caveat.

• Source: Endpts
• 643
• November 13, 2017